Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs

Benitec Biopharma Limited (NASDAQ:BNTC) – Equities researchers at Leerink Partnrs lowered their Q1 2026 earnings estimates for Benitec Biopharma in a report issued on Monday, November 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($0.29) for the quarter, down from their prior forecast of ($0.26). The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.04) EPS and FY2027 earnings at ($1.02) EPS.

Several other equities analysts have also recently issued reports on BNTC. Zacks Research cut shares of Benitec Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 6th. HC Wainwright lifted their price target on shares of Benitec Biopharma from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. JMP Securities set a $22.00 price objective on Benitec Biopharma in a research report on Tuesday, November 4th. Oppenheimer restated an “outperform” rating and issued a $29.00 target price (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Finally, Citizens Jmp boosted their target price on Benitec Biopharma from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.83.

Benitec Biopharma Price Performance

NASDAQ:BNTC traded down $0.35 during mid-day trading on Thursday, reaching $13.10. 25,956 shares of the stock were exchanged, compared to its average volume of 84,424. The company has a current ratio of 54.67, a quick ratio of 54.67 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average price of $14.48 and a 200 day moving average price of $13.76. Benitec Biopharma has a 1-year low of $9.10 and a 1-year high of $17.15. The firm has a market capitalization of $343.74 million, a PE ratio of -8.91 and a beta of 0.23.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.18).

Insider Activity at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 1,481,481 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $19,999,993.50. Following the completion of the acquisition, the director owned 9,538,175 shares in the company, valued at $128,765,362.50. This trade represents a 18.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently modified their holdings of BNTC. Infinitum Asset Management LLC raised its holdings in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock worth $14,636,000 after acquiring an additional 915,000 shares in the last quarter. Vanguard Group Inc. increased its position in Benitec Biopharma by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock worth $13,919,000 after purchasing an additional 22,948 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock worth $4,859,000 after purchasing an additional 181,391 shares in the last quarter. AWM Investment Company Inc. raised its stake in shares of Benitec Biopharma by 35.2% during the 1st quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock worth $1,795,000 after purchasing an additional 35,950 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Benitec Biopharma by 219.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock valued at $1,286,000 after buying an additional 75,507 shares during the last quarter. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.